The company Alexion has agreed to pay us authorities USD 21 million to resolve charges of bribing officials in Russia and Turkey during the promotion of the medicinal product SOLIRIS (eculizumab), according to The Wall Street Journal.
According to the position of the charges, units of Alexion paid to officials in Russia and Turkey, to achieve registration of the drug and to stimulate his appointment of patients. From 2011 to 2015 Alexion division in Russia paid more than $ 1 million to unnamed officials. The company neither deny nor agree with the charges.
SOLIRIS is designed to treat PNH and atypical Gemalto uremic syndrome.